These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 1856731

  • 1. Anti-presynaptic membrane receptor antibodies in myasthenia gravis.
    Lu CZ, Link H, Mo XA, Xiao BG, Zhang YL, Qin Z.
    J Neurol Sci; 1991 Mar; 102(1):39-45. PubMed ID: 1856731
    [Abstract] [Full Text] [Related]

  • 2. Immunological specificity and cross-reactivity of anti-acetylcholine receptor and anti-presynaptic membrane receptor antibodies in myasthenia gravis.
    Xiao BG, Lu CZ, Höjeberg B, Link H.
    J Neurol Sci; 1991 Sep; 105(1):118-23. PubMed ID: 1665503
    [Abstract] [Full Text] [Related]

  • 3. Myasthenia gravis: T and B cell reactivities to the beta-bungarotoxin binding protein presynaptic membrane receptor.
    Link H, Sun JB, Lu CZ, Xiao BG, Fredrikson S, Höjeberg B, Olsson T.
    J Neurol Sci; 1992 Jun; 109(2):173-81. PubMed ID: 1634899
    [Abstract] [Full Text] [Related]

  • 4. Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass.
    Whiting PJ, Vincent A, Newsom-Davis J.
    J Neuroimmunol; 1983 Aug; 5(1):1-9. PubMed ID: 6874919
    [Abstract] [Full Text] [Related]

  • 5. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis.
    de la Porte S, Ragueh F, Eymard B, Courbin P, Chapron J, Koenig J.
    J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074
    [Abstract] [Full Text] [Related]

  • 6. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN, Reddel SW, Gervásio OL, Phillips WD.
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [Abstract] [Full Text] [Related]

  • 7. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM, Van Den Broeck J, Vrolix K, Janssen SP, Lemmens MA, Van Der Esch E, Duimel H, Frederik P, Molenaar PC, Martínez-Martínez P, De Baets MH, Losen M.
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [Abstract] [Full Text] [Related]

  • 8. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S, Tsuji R, Oda K.
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [Abstract] [Full Text] [Related]

  • 9. Immunochemical properties of junctional and extrajunctional acetylcholine receptor.
    Dwyer DS, Bradley RJ, Furner RL, Kemp GE.
    Brain Res; 1981 Jul 27; 217(1):23-40. PubMed ID: 6167329
    [Abstract] [Full Text] [Related]

  • 10. Presynaptic membrane receptor-reactive T lymphocytes in myasthenia gravis.
    Yi Q, Pirskanen R, Lefvert AK.
    Scand J Immunol; 1996 Jan 27; 43(1):81-7. PubMed ID: 8560200
    [Abstract] [Full Text] [Related]

  • 11. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis.
    Hara H, Hayashi K, Ohta K, Itoh N, Nishitani H, Ohta M.
    Clin Chem; 1993 Oct 27; 39(10):2053-7. PubMed ID: 8403390
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis.
    Vernet-der Garabedian B, Morel E, Bach JF.
    J Neuroimmunol; 1986 Jul 27; 12(1):65-74. PubMed ID: 3711314
    [Abstract] [Full Text] [Related]

  • 13. Myasthenia gravis: prototype of the antireceptor autoimmune diseases.
    Schönbeck S, Chrestel S, Hohlfeld R.
    Int Rev Neurobiol; 1990 Jul 27; 32():175-200. PubMed ID: 1706686
    [No Abstract] [Full Text] [Related]

  • 14. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
    Gunji K, Skolnick C, Bednarczuk T, Benes S, Ackrell BA, Cochran B, Kennerdell JS, Wall JR.
    Clin Immunol Immunopathol; 1998 Jun 27; 87(3):276-81. PubMed ID: 9646837
    [Abstract] [Full Text] [Related]

  • 15. Alpha-bungarotoxin blocking antibodies in neonatal myasthenia gravis: frequency and selectivity.
    Vernet-der Garabedian B, Eymard B, Bach JF, Morel E.
    J Neuroimmunol; 1989 Jan 27; 21(1):41-7. PubMed ID: 2908881
    [Abstract] [Full Text] [Related]

  • 16. Pathophysiology of myasthenia gravis.
    Hughes BW, Moro De Casillas ML, Kaminski HJ.
    Semin Neurol; 2004 Mar 27; 24(1):21-30. PubMed ID: 15229789
    [Abstract] [Full Text] [Related]

  • 17. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
    Bionda A, De Baets MH, Tzartos SJ, Lindstrom JM, Weigle WO, Theophilopoulos AN.
    Clin Exp Immunol; 1984 Jul 27; 57(1):41-50. PubMed ID: 6611231
    [Abstract] [Full Text] [Related]

  • 18. Future therapeutic strategies in autoimmune myasthenia gravis.
    Psaridi-Linardaki L, Mamalaki A, Tzartos SJ.
    Ann N Y Acad Sci; 2003 Sep 27; 998():539-48. PubMed ID: 14592926
    [Abstract] [Full Text] [Related]

  • 19. [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis].
    Kalies I, Heinz F, Kaschka WP, Druschky KF, Kalden JR.
    Klin Wochenschr; 1984 Apr 16; 62(8):377-85. PubMed ID: 6727277
    [Abstract] [Full Text] [Related]

  • 20. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J, Wang ZY, Link H.
    J Neurol Sci; 1994 Feb 16; 121(2):190-3. PubMed ID: 8158214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.